Integration of polygenic risk scores with modifiable risk factors improves risk prediction: results from a pan-cancer analysis

ABSTRACT Cancer risk is determined by a complex interplay of genetic and modifiable risk factors. Combining individual germline risk variants into polygenic risk scores (PRS) creates a personalized genetic susceptibility profile that can be leveraged for disease prediction. Using data from the UK Biobank cohort (413,753 individuals; 22,755 incident cases), we systematically quantify the added predictive value of augmenting conventional cancer risk factors with PRS for 16 cancer types. Our results indicate that incorporating PRS in addition to family history of cancer and modifiable risk factors improves prediction accuracy, but the magnitude of incremental improvement varies substantially between cancers. We also demonstrate the utility of PRS for risk stratification. Individuals with high genetic risk (PRS≥80th percentile) have significantly divergent 5-year absolute risk trajectories across strata based on family history and modifiable risk factors. Finally, we estimate that high genetic risk accounts for 4.0% to 30.3% of new cancer cases, which exceeds the impact of many lifestyle-related risk factors. In summary, we provide novel quantitative data illustrating the importance of integrating PRS into personalized cancer risk assessment.

[1]  J. Witte,et al.  Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts , 2020, Nature Communications.

[2]  Benjamin Neale,et al.  Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults Implications for Primary Prevention , 2019 .

[3]  M. Inouye,et al.  Towards clinical utility of polygenic risk scores. , 2019, Human molecular genetics.

[4]  J. Danesh,et al.  Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke , 2019, Nature Communications.

[5]  M. Ikram,et al.  Genetic predisposition, modifiable risk factor profile and long-term dementia risk in the general population , 2019, Nature Medicine.

[6]  J. Witte,et al.  Pan-Cancer Study Detects Novel Genetic Risk Variants and Shared Genetic Basis in Two Large Cohorts , 2019, bioRxiv.

[7]  C. Friedenreich,et al.  The current and future burden of cancer attributable to modifiable risk factors in Canada: Summary of results. , 2019, Preventive medicine.

[8]  C. Friedenreich,et al.  The burden of cancer attributable to modifiable risk factors in Canada: Methods overview. , 2019, Preventive medicine.

[9]  D. Duggan,et al.  Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts , 2019, Cancer medicine.

[10]  Matthew S. Lebo,et al.  Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood , 2019, Cell.

[11]  Kristen S Purrington,et al.  Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.

[12]  Mathieu Lemire,et al.  Discovery of common and rare genetic risk variants for colorectal cancer , 2018, Nature Genetics.

[13]  I. Tzoulaki,et al.  The added value of genetic information in colorectal cancer risk prediction models: development and evaluation in the UK Biobank prospective cohort study , 2018, British Journal of Cancer.

[14]  M. Oudkerk,et al.  PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial , 2018, Journal of Thoracic Oncology.

[15]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[16]  S. Sharp,et al.  Development and Validation of Lifestyle-Based Models to Predict Incidence of the Most Common Potentially Preventable Cancers , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[17]  E. Topol,et al.  The personal and clinical utility of polygenic risk scores , 2018, Nature Reviews Genetics.

[18]  Stephanie E. Moser,et al.  Exploring various polygenic risk scores for skin cancer in the phenomes of the Michigan genomics initiative and the UK Biobank with a visual catalog: PRSWeb , 2018, bioRxiv.

[19]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[20]  Stephanie E. Moser,et al.  Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative , 2017, bioRxiv.

[21]  Julian Wolfson,et al.  Performance of the Net Reclassification Improvement for Nonnested Models and a Novel Percentile-Based Alternative , 2018, American journal of epidemiology.

[22]  P. Pharoah,et al.  Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study , 2018, Journal of Medical Genetics.

[23]  N. Malats,et al.  Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. , 2018, International journal of epidemiology.

[24]  A. Gavin,et al.  The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015 , 2018, British Journal of Cancer.

[25]  Peter Kraft,et al.  Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer , 2018, Nature Communications.

[26]  Thomas A. Gerds,et al.  riskRegression: Predicting the Risk of an Event using Cox Regression Models , 2017, R J..

[27]  C. Sudlow,et al.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.

[28]  S. Vansteelandt,et al.  Doubly robust estimation of attributable fractions in survival analysis , 2017, Statistical methods in medical research.

[29]  Martin Eklund,et al.  Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial , 2017, Journal of the National Cancer Institute.

[30]  E. Boerwinkle,et al.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.

[31]  A. Sjölander,et al.  Model-based estimation of the attributable fraction for cross-sectional, case–control and cohort studies using the R package AF , 2016, European Journal of Epidemiology.

[32]  T. Marteau,et al.  The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis , 2016, British Medical Journal.

[33]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[34]  Witold Zatonski,et al.  European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. , 2015, Cancer epidemiology.

[35]  Pui-Yan Kwok,et al.  A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. , 2015, Cancer discovery.

[36]  杜昕,et al.  Systematic review with meta–analysis , 2015 .

[37]  Olga V. Demler,et al.  Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.

[38]  K. D. Sørensen,et al.  Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[39]  M. Kattan,et al.  Calibration plots for risk prediction models in the presence of competing risks , 2014, Statistics in medicine.

[40]  B. Brunekreef,et al.  Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). , 2013, The Lancet. Oncology.

[41]  Janet W. Dyk,et al.  SUMMARY OF RESULTS , 1968, Virtual Pilgrimage.

[42]  M. Pencina,et al.  Understanding increments in model performance metrics , 2012, Lifetime Data Analysis.

[43]  Nilanjan Chatterjee,et al.  Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. , 2013, Cancer research.

[44]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[45]  Josyf Mychaleckyj,et al.  Robust relationship inference in genome-wide association studies , 2010, Bioinform..

[46]  M. Greene,et al.  Family history of breast cancer as a risk factor for ovarian cancer in a prospective study , 2006, Cancer.

[47]  Patrick Royston,et al.  Explained Variation for Survival Models , 2006 .

[48]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[49]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[50]  J Benichou,et al.  Estimates of absolute cause-specific risk in cohort studies. , 1990, Biometrics.

[51]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[52]  L. Döbrőssy,et al.  [European Code against Cancer: 12 ways to reduce your cancer risk]. , 2016, Orvosi hetilap.

[53]  R. Kurtz,et al.  Epidemiology of pancreatic cancer and the role of family history , 2013, Journal of surgical oncology.